Company Performance - In the first half of 2025, the company achieved revenue of 156 million yuan, representing a year-on-year growth of 17.66% [1] - The net profit attributable to shareholders was 48.21 million yuan, with a year-on-year increase of 67.10% [1] R&D and Product Development - The company focuses on key surgical procedures, with core products including various types of surgical staplers and support products, addressing clinical needs such as tissue separation, excision, organ function reconstruction, and intraoperative hemostasis [2] - The main revenue driver is the minimally invasive endoscopic products, which include disposable endoscopic cutting staplers and electric endoscopic cutting staplers, widely used in various minimally invasive surgeries [2] - R&D investment reached 18.89 million yuan in the first half of 2025, up 21.34% year-on-year, with R&D expenditure accounting for 12.10% of revenue [2] - The company applied for 11 new patents globally and received 53 new patent authorizations, including 44 core technology invention patents [2] Product Pipeline and Market Expansion - The company is accelerating its layout around "ultra-minimally invasive + intelligent" dual lines, with products like the "TSN electric stapler" already registered in two overseas countries [3] - The "third-generation endoscopic cutting stapler and nail warehouse" has completed multiple rounds of testing and is about to enter the registration process [3] - The company is also advancing its smart surgical platform project, which has made significant progress in key technologies and is entering the first product release and industrialization phase [3] Industry Outlook - The global medical device market is projected to reach 623 billion USD by 2024, with a compound annual growth rate (CAGR) of 6.9% from 2019 to 2024, and expected to grow to 869.7 billion USD by 2030 [4] - The demand for minimally invasive and robotic surgeries is driving significant growth in the surgical instrument sector, with the company well-positioned to benefit from this trend due to its technological and patent advantages [4] Strategic Initiatives - The company is enhancing its domestic and overseas dual-drive strategy, ensuring stable supply of selected products under national procurement policies while dynamically assessing market competition [5] - The company plans to issue a high dividend payout, distributing 5 yuan per 10 shares, totaling 40.33 million yuan, which accounts for 83.66% of the net profit attributable to shareholders for the first half of the year [5][6]